<DOC>
	<DOC>NCT00718588</DOC>
	<brief_summary>This is a Phase I multicenter study that will be conducted in the United States and consists of a double-blind, placebo-controlled, SAD stage, followed by a double-blind, placebo controlled MAD stage. The study will be conducted in approximately 65 adult patients between 18 and 80 years old who have RA.</brief_summary>
	<brief_title>A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>1. SAD Stage RA diagnosed according to the ACR For patients taking antirheumatic therapies, receipt of a stable regimen prior to randomization Previous treatment with biologic agents, including antiTNF agents, permitted but discontinued for an appropriate washout period 2. MAD Stage (same as above with the addition of the following) Failure of at least one biologic agent, defined as lack of or loss of response or intolerance Active disease defined by swollen and tender count Significant systemic involvement of RA, including vasculitis, pulmonary fibrosis, or Felty's syndrome Malignancy, or prior malignancy, other than nonmelanoma skin cancer or cervical carcinoma in situ that has been resected History of treatment with any T celldirected therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>RA</keyword>
</DOC>